Loading news...
ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.
Intuitive Surgical, Inc. dominates surgical robotics with an 80% global share and a robust, recurring-revenue business model anchored by the da Vinci platform. ISRG's installed base and procedure volumes continue double-digit growth, driven by superior clinical outcomes and high hospital switching costs. Despite premium valuation (forward P/E ~64), ISRG's pristine balance sheet, strong margins, and relentless innovation justify a long-term Buy rating.
The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $585.08, representing a -1.21% change from its previous close.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ISRG trades just 4% below its record high after a 32% surge over the past three months, driven by strong procedure growth, rising utilization, and early traction for the da Vinci 5 system.
ISRG stock has climbed nearly 40% from its October 2025 lows of approximately $425, currently trading near $590. What has spurred this remarkable rise?
Intuitive Surgical is a leading provider of surgical robotics devices. Its da Vinci robot was one of the first to market and boasts a massive installed base.
Robotics is poised for steady growth in 2026. Consider PATH, NVDA, CDNS and ISRG for potential market dominance across sectors.
Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.
Growth companies are usually afforded a premium by the market. If you hold for the long term, say a 20-year period, a company's growth can compensate for a lofty valuation at the time of purchase.
This selection of stocks offers interesting buys throughout industries -- from tech to healthcare. Many of these players are trading at bargain levels.
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
GoalVest Advisory LLC cut its position in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 96.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 124 shares of the medical equipment provider's stock after selling 3,040 shares during the period.
Stanley Laman Group Ltd. increased its holdings in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 2,091.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,456 shares of the medical equipment provider's stock after acquiring an additional 12,842 shares
Blue Sky Capital Consultants Group Inc. increased its stake in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 13.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,748 shares of the medical equipment provider's stock after buying an additional 1,035
Intuitive Surgical is a pioneer in robotic-assisted surgery. Despite increasing competition, its innovative ability and strong moat should help protect its market share.
Generali Asset Management SPA SGR grew its stake in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 6.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,467 shares of the medical equipment provider's stock after acquiring an additional 1,316 shares during the quarter.
Financial Consulate Inc. purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,183 shares of the medical equipment provider's stock, valued at approximately $529,000. Several other hedge
Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) and Intuitive Surgical (NASDAQ: ISRG - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Earnings and Valuation This table compares Lucid Diagnostics
Several factors could help Intuitive Surgical's stock soar through 2031, despite recent challenges. Meta Platforms' results might justify its AI investments.